Document is current

Article History

Received: 4 February 2024

Accepted: 17 March 2024

First Online: 25 March 2024

Declarations

:

: Secondary analysis of anonymised individual patient data was deemed as minimal risk research by the Southern Adelaide Local Health Network, Officer for Research and Ethics, and was exempted from review. Patient consent is not required for secondary analysis of anonymised clinical study data utilised in the present investigation. All patients provided written informed consent for participating IMpower130 and IMpower150 clinical trials as previously reported.

: Not required for secondary analysis of anonymised individual patient data.

: L.X.L, G.K, A.S, and A.M.H have no conflicts of interest to disclose.M.J.S reports investigator-initiated project grants from Pfizer, outside the submitted work.M.A.S reports receiving research grants paid to institution from Genentech, Spectrum, Cullinan, Takeda, Diaachi-Sanyko, Enliven, Beigene, OncoC4, serving on a speakers bureau for AZ, Regeneron, Lilly, Genentech, G1 Therapeutics, Guardant, Janssen, Jazz, Mirati, serving on the steering committee/DSMB for Beigene, BMS, Genentch, Summit, and serving an advisory role with Beigene, Genentech, Spectrum, Lilly, OncoC4, Gilead, Mirati, outside the submitted work.C.S.K reports serving an advisory board role with AstraZeneca, Merck, Roche, Beigene, Jannsen, Gilead, Takeda, Eisai, and BMS.R.A.M reports investigator-initiated project grants from Pfizer, outside the submitted work.A.R reports investigator initiate grant funding outside of the scope of the current project from AstraZeneca, Boehringer Ingelheim and Pfizer, and declares payment of speakers fees for presentations outside of the scope of the current work from Boehringer Ingelheim and Genentech.